ClinicalTrials.gg
CompletedNCT04381689Updated Jul 8, 2026

Phase 3 Study to Evaluate the Immunogenicity and Safety of Inactived Split Influenza Vaccine in Healthy Infants

A Phase 3 interventional study of IL-YANG FLU Vaccine Prefilled Syringe INJ. and Fluarix Tetra Pre-filled Syringe in Healthy, sponsored by Il-Yang Pharm. Co., Ltd.. Completed at 2 sites in South Korea. Open to participants aged 6 Months to 3 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-08.

Sponsored by Il-Yang Pharm. Co., Ltd. · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
260
Allocation
Randomized
Ages
6 Months to 3 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 60 studies in Influenza, Human with a site in Korea, Republic of — 9 open to participants now, 10 under way, 4 of them phase 3. Influenza, Human · Korea, Republic of.

Enrollment
29th of 55
260 · median 274
Started
2024
with 2 others
Phase 3
28 of 60
3 open now
Registered
41st of 60
by date
Lead sponsor
4 of 60
Il-Yang Pharm. Co., Ltd.

Among the 60 studies in Influenza, Human with a site in Korea, Republic of, this one is the 29th largest by enrollment of the 55 interventional ones that give a count, is one of 3 that started in 2024, is one of 28 in phase 3, and was the 41st registered.

Influenza, Human

2,360 studies on the registry are indexed under Influenza, Human; 185 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

9 of the 60 studies in Influenza, Human with a site in Korea, Republic of are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 123 Influenza, Human studies recruiting now, 66 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 68 take healthy volunteers.

This study: 6 Months to 3 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies in Influenza, Human with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and immunogenicity of IL-YANG Inactivated Split Influenza Vaccine (IL-YANG Quadrivalent Seasonal Influenza Vaccine) in healthy infants from 6 months to under 3 years of age(≥ 6 months and \< 3 years)

Read the detailed description

The study is an Randomized, Double-blind, Active controlled Phase III study.

03

Conditions studied

  • Healthy

Browse trials for

Keywords

  • Influenza
  • Influenza vaccine
  • Split influenza vaccine
  • Seasonal influenza vaccine
04

Who can participate

Ages eligible
6 Months to 3 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy infants 'from 6 months to under 3 years of age (≥6 months and \<3 years)
  2. Born after normal gestation period (which is more than 37 weeks)
  3. A subject's legally acceptable representative has voluntarily decided on participation and provided written after receiving and understanding a detailed explanation on this study

Exclusion criteria

Exclusion Criteria:

  1. A history of severe reactions (e.g., anaphylaxis) to eggs, chicken, and other components of a vaccine including those derived from chicken
  2. A history of influenza vaccination within 6 months prior to screening
  3. Immuno dysfunction including immunodeficiency diseases or a family history thereof
  4. A history of Guillain-Barre syndrome
  5. Down's syndrome or cytogenetic disorders
  6. Severe chronic diseases (e.g., cardiovascular diseases excluding controlled hypertension, respiratory diseases with respiratory failure, metabolic diseases, renal dysfunction, hemoglobinopathy, etc.) that, in the opinion of investigator, preclude a subject's participation in the study
  7. Risk of serious bleeding from an IM injection such as hemophilia patients or those on anticoagulants
  8. Acute fever with body temperature exceeding 38.0℃ within 72 hours prior to vaccination with the IP
  9. Vaccinated with other vaccines within 28 days prior to screening
  10. Received or immune-modifying drugs within 3 months prior to screening

    ① Azathioprine, cyclosporin, interferon, granulocyte colony-stimulating factor (G-CSF), tacrolimus, everolimus, sirolimus, etc.

    ② Use of high-dose (e.g., continued use of prednisolone at a dose of ≥2 mg/kg/day in subjects weighing \<10 kg for 14 days or longer or at a dose of ≥20 mg/day in subjects weighing ≥10 kg for 14 days or longer). However, inhaled, intranasal, or topical corticosteroids are permitted regardless of their dose.

  11. Prior use of immunoglobulin or blood products within 3 months prior to screening or their anticipated use during the study
  12. Took antipyretics, analgesics, or non-steroidal anti-inflammatory drugs (NSAIDs) within 4 hours prior to vaccination with the IP
  13. Participated in another clinical study within 6 months prior to screening
  14. Determined ineligible based on other medical or psychiatric findings by the investigator
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
260 participants (actual)

Study arms

  • Experimental
    IL-YANG FLU Vaccine Prefilled Syringe INJ.

    Teratect Prefilled Syringe Inj. 0.5mL

    Biological: IL-YANG FLU Vaccine Prefilled Syringe INJ.

  • Active comparator
    GSK FLU Vaccine Prefilled Syringe INJ.

    Fluarix Tetra Pre-filled Syringe 0.5mL

    Biological: Fluarix Tetra Pre-filled Syringe

Interventions

  • BiologicalIL-YANG FLU Vaccine Prefilled Syringe INJ.

    Teratect Prefilled Syringe Inj. 0.5mL

  • BiologicalFluarix Tetra Pre-filled Syringe

    Fluarix Tetra Pre-filled Syringe 0.5mL

06

What researchers measure

Primary outcomes

  1. Primary immunogenicity endpoints

    1. (Seroconversion rate† is) Proportion of subjects achieving seroconversion\* for HI antibody after vaccination with the IP† † Seroconversion rate (SCR) \* Seroconversion: * A pre-vaccination (prior to vaccination with the IP, Day 0) HI antibody titer \<1:10 and a post-vaccination (at Day 28 after the last vaccination with the IP) HI antibody titer ≥1:40 * A pre-vaccination (prior to vaccination with the IP, Day 0) HI antibody titer ≥1:10 and at least a 4-fold increase in post-vaccination (at Day 28 after the last vaccination with the IP) HI antibody titer 2. (Seroprotection rate‡ is) Proportion of subjects achieving seroprotection\*\* for HI antibody after vaccination with the IP‡ ‡ Seroprotection rate (SPR) \*\* Seroprotection: HI antibody titer ≥1:40 at Day 28 after the last vaccination with the IP

    Time frame: From a pre-vaccination (prior to vaccination with the IP, Visit1) to a post-vaccination (at Day 28 after the last vaccination with the IP)

  2. Seroprotection rate against Hemagglutination

    Seroprotection rate(a lower bound of 95 CI) ≥ 70%

    Time frame: Up to Day28(+7) after the last vaccination

Secondary outcomes

  1. Geometric Mean Titer(GMT)

    GMT of HI Antibody Titer Before Vaccination and After Vaccination

    Time frame: Up to Day28(+7) after the last vaccination

  2. Geometric Mean Ratio(GMR)

    GMR of HI Antibody Titer Before Vaccination and After Vaccination

    Time frame: Up to Day28(+7) after the last vaccination

07

Study locations

2 sites
  • Korea University ANSAN Hospital
    Ansan-si, Gyeonnggi-do 15355, South Korea
  • The Catholic University of Korea, Bucheon St. Mary's Hospital
    Bucheon-si, Gyeonnggi-do 15355, South Korea
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2024 to primary completion in May 2025, 6 months.

Of 119 industry-sponsored phase 3 interventional studies under Influenza, Human, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 14. This study's 6 months is below that.

Counting every sponsor, half of 154 studies reached it within 8 months; a quarter within 4 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2020
First posted
May 11, 2020
StartActual
Oct 23, 2024
Primary completionActual
May 20, 2025
CompletionActual
Oct 22, 2025
Last update
Jul 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04381689
Responsible party
Sponsor
First posted
May 11, 2020
Start date
Oct 23, 2024
Primary completion
May 20, 2025
Completion
Oct 22, 2025
Last update
Jul 8, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion